Market LIVE
Published markets; coverage varies by country
Product profile · United States

BYSANTI

 ·  Patent Litigation & Settlement History ↓

IngredientMILSAPERIDONE
Application typeNDA
Application220358
Product003
Dosage formTABLET
RouteORAL
Strength4MG
Approval date2026-02-20
Marketing statusPrescription
Status event—
ApplicantVANDA PHARMS INC
Product source

Current GenericRadar decision

Year2031
SelectionDEEP_REVIEW
ReviewFINAL
Anchor typeREGULATORY_EXCLUSIVITY
Anchor date2031-02-20
Patent anchor—
Exclusivity anchor2031-02-20
Protection date—
First Final ANDA—
Status event—

GNR judgment: DEEP_REVIEW. Reference year: 2031. Anchor type: REGULATORY_EXCLUSIVITY. Patent anchor: not recorded. Exclusivity anchor: 2031-02-20. Anchor date: 2031-02-20. Patent tail: yes. Exclusivity tail: no. Review status: FINAL. Historical detailed rationale is retained in the evidence snapshot; this is a structured English summary, not a literal translation.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
105704532028-03-28U U-4436———
———
105704532028-03-28U U-4437———
———
91571212030-04-05U U-4436———
———
91571212030-04-05U U-4437———
———
105632592030-07-24U U-4436———
———
105632592030-07-24U U-4437———
———
126068692030-09-22U U-4507———
———
126068692030-09-22U U-4506———
———
89996382030-10-28U U-4436———
———
89996382030-10-28U U-4437———
———
90742552030-12-17U U-4437———
———
90742552030-12-17U U-4436———
———
90727422031-01-16U U-4436———
———
90727422031-01-16U U-4437———
———
90742562031-02-10U U-4437———
———
90742562031-02-10U U-4436———
———
90742542031-12-28U U-4436———
———
90742542031-12-28U U-4437———
———
124786192044-05-31U U-4435———
———
124786192044-05-31U U-4434———
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
NCE—2031-02-20————Source

2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.